TSXV:BTI.H - Post by User
Post by
Sir_Holleron Jun 20, 2015 9:20am
174 Views
Post# 23851598
RNAi
RNAiFor advancing RNAi in the liver, though not through Phase III yet, ALNY's market capitalization hit a record C$14.5 billion on Friday. Piper put a C$18.5 billion target price on it this week.
Being the first to deliver to the brain of a living animal with therapeutic effect, when will BTI publish the details of its stroke results in a scientific peer review journal? Sketchy results were released over 3 months ago in a news release. BTI also paid for an analyst report and announced the reports release to shareholders in a news release. The analyst report expected BTI to commence human trials this year. BTI has said that it was aggressivly pursuing human clinical trials. In a presentation BTI also had ALS on its agenda. The stroke study was undertaken to support licensing.
Published RNAi results(first proof in living animals for efficacy),
Published results with Herceptin,
Published Lysosomal Storage Disease results,
Commencement of human testing for all three.
Deals on Herceptin, RNAi...
Commencement of human testing.